Published in World J Virol on February 12, 2013
Calyculin A, an enhancer of myosin, speeds up anaphase chromosome movement. Cell Chromosome (2007) 0.87
Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site. Bioorg Med Chem Lett (2014) 0.85
MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol (2014) 0.83
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. BMC Infect Dis (2014) 0.79
Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol (2015) 0.78
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol (2016) 0.76
Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance. F1000Res (2016) 0.75
Advanced molecular surveillance of hepatitis C virus. Viruses (2015) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature (2005) 17.47
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A (1990) 8.92
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol (2004) 6.67
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (2003) 6.01
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 5.47
Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A (2005) 5.31
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis (2008) 2.69
In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol (2003) 2.55
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother (2008) 2.22
Hepatitis C virus resistance to protease inhibitors. J Hepatol (2011) 2.18
Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis (2012) 2.04
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology (2000) 1.72
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology (2011) 1.62
Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol (2009) 1.58
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother (2012) 1.56
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat (2012) 1.50
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother (2008) 1.47
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother (2009) 1.42
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother (2010) 1.42
Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol (2008) 1.40
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One (2011) 1.39
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol (2012) 1.35
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol (2012) 1.35
Resistance to anti-HCV protease inhibitors. Curr Opin Virol (2011) 1.30
Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol (2011) 1.25
Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev (2007) 1.24
Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Ther Pat (2009) 1.24
Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology (2011) 1.23
Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother (2011) 1.22
Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res (1997) 1.21
Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol (2008) 1.19
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver (2011) 1.17
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother (2012) 1.16
Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother (2006) 1.14
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis (2010) 1.14
Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther (2008) 1.13
Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol (2008) 1.11
In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother (2007) 1.09
Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology (2011) 1.08
Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol (2005) 1.08
Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother (2011) 1.06
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepat (2011) 1.03
Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol (2011) 0.96
Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol (2005) 0.95
Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol (2002) 0.92
Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med (2010) 0.91
Infectious diseases. First specific drugs raise hopes for hepatitis C. Science (2011) 0.88
Nucleotide prodrugs for HCV therapy. Antivir Chem Chemother (2011) 0.88
Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2010) 0.86
Treatment of non-genotype 1 hepatitis C virus patients. Curr Gastroenterol Rep (2012) 0.82
Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol (2011) 0.82
Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates. J Viral Hepat (2010) 0.76
ARHAI: antiviral resistance. J Antimicrob Chemother (2012) 0.76
Recombination in hepatitis C virus. Viruses (2011) 1.05
Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV. Int Microbiol (2014) 0.78
Genomic medicine reaches HCV-related liver transplantation: hopes and clinical and public health implications. J Hepatol (2011) 0.75
Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. J Clin Virol (2012) 0.75
New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics (2012) 0.75
[Meeting Report: 20 years after the First International Symposium on hepatitis C virus and related viruses]. Gastroenterol Hepatol (2013) 0.75
Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients. Infect Genet Evol (2012) 0.75
Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients. Infect Genet Evol (2010) 0.75